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Background: Balance problems contribute to reduced quality of life in Parkinson’s disease (PD) and
available treatments are often insufﬁcient for treating axial and postural motor symptoms.
Objective: To investigate the safety of use and possible effects of stochastic vestibular stimulation (SVS)
alone and combined with LDOPA in patients with PD.
Methods: SVS or sham stimulation was administered to 10 PD patients in a double-blind placebo
controlled cross-over pilot study. Motor symptoms and balance were evaluated in a deﬁned off-
medication state and after a 200 mg test dose of LDOPA, using UPDRS-III, Posturo-Locomotor-Manual
(PLM) movement times (MT), static posturography and force plate measurements of the correcting
response to a balance perturbation.
Results: Patients did not detect when SVS was active, but SVS increased nausea after LDOPA in two
patients. Mixed model analysis demonstrated that SVS improved balance corrections after a backward
perturbation and shortened the postural response time. In static posturography there was signiﬁcant
interaction between effects of SVS, medication and proprioceptive input (standing on foam vs. on hard
support) and SVS decreased the total sway-path with eyes closed and off medication.
As expected, LDOPA improved the UPDRS-III scores and MT. There was an interaction between the effect
of SVS and LDOPA on UPDRS-III partly because of reduced UPDRS-III scores with SVS in the off-
medication state.
Conclusions: Short term use of SVS is safe, improves corrective postural responses and may have a small
positive effect on motor symptoms in PD patients off treatment.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Treatments for Parkinson’s disease (PD) motor symptoms are
usually more effective for appendicular extremity symptoms than
axial symptoms. Postural instability in particular, is often partly
treatment resistant to both LDOPA and deep brain stimulation
(DBS) [1]. Dopaminergic treatments can sometimes increase bal-
ance problems, especially when they elicit dyskinesia [2] orP, center of pressure; PLM,
e; SR, stochastic resonance;
n; SVS, stochastic vestibular
t at the 18th International
ders in Stockholm 2014.
.
Inc. This is an open access article ucognitive impairments [3]. Non-dopaminergic treatments such as
deep brain stimulation of the subthalamic nucleus (STN-DBS) is not
suitable in patients biologically aged over 70, with cognitive decline
or psychiatric comorbidity [3,4]. As balance problems have a strong
negative impact on quality of life, there is need for other treatments
that either improve balance or improve Parkinson symptoms
without adverse effects on balance.
Stochastic galvanic vestibular stimulation (SVS) is a non-invasive
method which activates the vestibular system in a random fashion,
so that the stimulation is not perceived as a perturbation of balance.
Balance can be improved by SVS in healthy controls and in patients
with Parkinson’s disease [5,6]. There is also some evidence that SVS
improves other symptoms in other neurodegenerative diseases,
including autonomic responses, motor function and frontal execu-
tive function when currents higher than detection threshold are
used [7,8]. A proposed explanation for both sub- and supra-
threshold effects is that SVS induces a phenomenon of stochasticnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Study subject characteristics.
Subject Sex Age of onset Age at testing PD dominant
side
Daily LDEa (mg) Hoehn & Yahr
Scale
T1 (mA) T2 (mA) AE
1 M 45 52 Right 845 2.5 0.9 0 N/A
2 F 53 62 Right 825 3 0 0.6 N/A
3 M 64 70 Left 1000 3 0 0.45 N/A
4 M 50 62 Right 154 2 0 0.6 N/A
5 F 38 44 Right 300 2 0 0.4 b
6 M 62 66 Left 1670 2.5 0 0.9 N/A
7 F 59 64 Right 650 2.5 0.35 0 c
8 M 60 62 Right 400 2 0.1 0 N/A
9 F 52 60 Right 710 2 0.3 0 d
10 M 52 70 Left 820 2.5 0.4 0 e
Half of the subjects received active stimulation and half received sham stimulation (0 mA) on test day 1 (T1). The reversed stimulation condition was applied on day 2 (T2). AE,
adverse effects reported by the subjects.
a Calculated as recommended in Tomlinson et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 2010;25(15):2649e53.
b T1 ¼ slight nausea þ stomach discomfort 1 h post LDOPA, T2 ¼ slight nausea 30 min post LDOPA þ vomit 45 min and 90 min post LDOPA.
c T2 ¼ slight vertigo during movement.
d T1 ¼ mild headache þ mild dizziness, T2 ¼ dry mouth 1 h post LDOPA.
e T1 ¼ slight nausea 45 min post LDOPA.
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vated systems with suboptimal function and can result in improved
signal detection as well as improved network function on higher
levels. For detailed discussions on SR see recent reviews [9e11]. The
exact mechanism of how SVSmay inﬂuence the activity of the brain
is not known, but may theoretically involve SR effects on thresholds
in the activation pattern of basal ganglia output. SVS has been
demonstrated to inﬂuence resting state electroencephalography
activity indicating that corticalesubcortical activity is also modu-
lated [12]. A recent rodent study demonstrated improved balance
and locomotion in the rotarod test in 6-OHDA hemilesioned rats
during near detection threshold SVS [13]. SVS was additionally
found to increase GABA-levels in the substantia nigra pars reticulata
(SNr) in a fashion similar to that seen after LDOPA treatment or
subthalamic stimulation [13,14], suggesting a possible neuro-
chemical mechanism for improved motor function in PD during
SVS, involving inhibition of the SNr, a nucleus which is overactive in
PD [15,16].
In previous studies of SVS in neurodegenerative diseases, motor
improvement effects have not been evaluatedwith standard clinical
scales, thus it is not clear if the improvement is large enough to be
of clinical signiﬁcance [5,7,8]. . Importantly, despite the encouraging
ﬁndings mentioned, the clinical efﬁcacy of SVS in PD has not been
determined and it is not known whether SVS effects interact at all
with the effect of LDOPA. The current investigation is a randomized
cross-over placebo controlled pilot study of the safety and feasi-
bility of SVS, with efﬁcacy on balance and motor symptoms as
secondary objectives. Although it was not powered to detect minor
improvements it can indicate what kind of effects can be expected
using the widely accepted UPDRS-III motor symptom rating scale.
Unlike previous studies, the effects of SVS were also compared with
the effect of LDOPA.Material and methods
The study was approved by the regional Ethical Review Board in
Gothenburg, Sweden (permission no 754-11) and informed written
consent was obtained prior to inclusion.Subjects
Ten patients with Parkinson’s disease fulﬁlling UKPDS brain
bank criteria [17] (6 males and 4 females, 61  8 years of age,
Table 1) were recruited from the Neurology Clinic at SahlgrenskaUniversity Hospital in Gothenburg, Sweden. Inclusion criteria were
a clinical effect of LDOPA medication and Hoehn and Yahr stage 3.
Exclusion criteria were implanted electronic devices as well as
ongoing or previously diagnosed vestibular diseases.Procedure
The study was carried out on 2 different days in a randomized
cross-over design. Subjects were block-randomized to treatment
arm A or B, which differed in whether active stimulation or sham
stimulation of 0 mA was present on the ﬁrst or the second test day
(Suppl. Fig. S1). The effects of SVS or sham SVS were evaluated after
12 h of medication abstinence as well as after a single open label
dose of dispersed LDOPA, Madopar Quick, 200 mg.
Stochastic electric currents were applied to the vestibular sys-
tem through oval 4  6 cm electrodes (Axelgaard Manufacturing,
CA, USA) placed over the mastoid process behind both ears, in a
bipolar binaural conﬁguration. For best possible electrode contact
and to avoid skin sensations during the stimulation, the skin behind
the ears was cleaned thoroughly with Nuprep skin prep gel
(Weaver and Company, USA). A generous amount of Skintact ECG
electrode gel (Leonhard Lang, Austria) was applied on the elec-
trodeswhichwere placed ﬁrmly on the cleaned area. The electrodes
were held in place by a soft pad and secured by an elastic head band.
The electrode impedance was measured repeatedly and was
conﬁrmed to be no more than 1 kU across evaluations. A portable
and programmable constant current stimulator [6] was used to
deliver the stimulus. Before evaluations commenced, the individual
threshold for stimulation induced perceptible sway was deter-
mined. Whilst blindfolded, subjects were seated on a stool placed
on a Kistler force plate (model 9260AA, Kistler Nordic AB, Sweden).
A sinusoid-shaped bipolar signal with a frequency of 1 Hz was
applied at eleven amplitude levels ranging between 0.1 mA and
0.7 mA (peak to peak), in two subsequent trials. Each amplitude
level was presented for a period of 10s followed by 5 s of 0 mA in a
ﬁxed pseudorandomized order. The lowest amplitude level where
rhythmic sway was recorded by the force plate software (BioWare
software version 5.0.3.0, Kistler Nordic AB, Sweden) or consistently
reported by the subject was recorded as the individual sinusoidal
threshold amplitude. Two subjects did not respond to0.7 mA and
a similar protocol with eight amplitude levels between 0.5 mA
and 1.2 mA was used. The individual stimulation threshold was
used as the maximum allowed amplitude of the SVS protocol. A
white noise stimulation pattern (0e30 Hz) was generated using a
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Figure 1. Dynamic “pull-release” posturography. A) Schematic explanation of the procedure where the subject counterbalances 3% of his/her weight and the weight is suddenly
released without prior notice. B) Typical dynamic posturography center of pressure (COP) registration: 1the corrective response time was the time(s) between T ¼ 2.0 s and the
change of movement direction; 2the difference between stable anterior-posterior (AP) position before and after release was calculated from a stable 2 s period after the corrective
movement (usually at t ¼ 6e8s); 3the release AP excursion (cm) was calculated as the maximum deviation in relation to the new stable AP CO) position; 4mediolateral movement
(m) was calculated as the maximum deviation to either side of the medial axis during the corrective response, resulting in two values per trial; 5the baseline average over
T ¼ [0.9 se2.0 s] was used as start reference point. C) Mean AP COP of registrations from all subjects during OFF medication state. Data from 9 healthy controls (age 22e68) are also
included for comparison. D) Mean AP COP registrations after LDOPA. Data from healthy controls is included as in C.
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Butterworth ﬁlter with the cutoff frequency set at 30 Hz. The
generated signal was conﬁrmed to have a zeromean (1%) and root
mean square (RMS) [(30 mA RMS/100 mA)  5%]. Like in previous
animal study [13], the SVS current was never higher than the
threshold amplitude and for 90% of the time it was less than 45% of
the threshold and was within the top 10% of current values for less
than 5% of the time. This can be compared with the sinusoidal test
current where the current level distribution is skewed toward the
maximum and minimum values so that it is within the top 10% of
current levels for 30% of the time. The used SVS current waveform
allows for blinded procedures and has been demonstrated to alter
basal ganglia GABA release and motor performance in 6-OHDA
hemilesioned rats [13].
SVS was either on or off during the entire evaluation period
(3h). When SVS was started, the stimulator ramped up the
amplitude over the ﬁrst 3 s to avoid sudden stimulation sensations.
Neither participants nor examiners were blinded to LDOPA
medication. The study was carried out according to the intended
double-blind design for SVS by using pre-programmed stimulation
protocols and masking all current indications on the device with
black tape.
Evaluations
Patients were encouraged to report any discomfort or adverse
reaction during the test day. At the end of the day subjects were
debriefed using a structured interview protocol (Suppl. Appendix A).
A dynamic perturbed balance response test was carried out on a
force plate (Kistler Nordic AB, Sweden, Fig. 1). A thin rope was
connected to a ﬁgure-of-8 harness worn by the subject. The rope
was loaded with 3% of the subject’s body weight, which pulled atthe height of the manubrium sterni. The subject stood on the force
plate while counterbalancing the pull and looking straight ahead at
a marker at eye level. Without prior notice the examiner released
the pull force by disengaging an electromagnetic holding magnet.
This created a spontaneous backward sway which the subject
reﬂectively corrected. The perturbation achieved with this setup is
analogous to the clinical push/release test [18], but much less
pronounced so will not elicit a stepping response, only a COP sway.
The COP sway movements in anterioposterior (Y) and mediolateral
(X) directions, as well as the perturbation correction time(s) were
recorded with BioWare acquisition software (Kistler Nordic AB,
Sweden) and analyzed. The mean COP position during 1.1 s
immediately before the pull-release was used as the starting point
for assessing sway-response to the perturbation. The perturbed
balance test was repeated 3e4 times for each treatment condition
and mean responses were used for statistical calculations.
Two static balance tests were also executed. During the ﬁrst,
subjects stood barefoot directly on the force plate with feet
together, arms folded over the chest and eyes closed. Four
consecutive 10s trials were recorded. The procedure was repeated
with the subject standing on a 10  50  50 cm pad of medium
density foam to decrease proprioceptive input. The overall center of
pressure (COP) sway-path and maximum sway (absolute distance
from the mean COP position derived from the COP postural mea-
surements) were analyzed.
A trained examiner performed UPDRS section III scoring while
blinded to stimulation, but not to medication status. The exami-
nation was recorded using a full HD camcorder and was scored
immediately and on a later occasion off line, with maintained
blinding for stimulation status. For rigidity items the ﬁrst assess-
ment was used, for the other measurements the off-line scoring
was used. When total scores (excluding rigidity items) differed by
Table 2
Summary of effects and collapsed estimates.
Mean  SD difference of collapsed estimates (P-value for main effect) P-values for interactions
SVS vs. sham SVS LDOPA
ON vs. OFF
No Foam vs. Foam SVS  LDOPA SVS  Foam LDOPA  Foam SVS  LDOPA 
Foam
Correction time1 0.05  0.03 s (0.001) 0.04  0.09 s (0.21) 0.054
Stable pre-post release
position2, Dy
0.5  0.6 cm (0.05) 0.1  1.3 cm (0.72) 0.12
Release AP deviation3, Dy 0.9  1.0 cm (0.01) 0.1  1.3 cm (0.77) 0.02
Release ML deviation4, Dx 0.2  0.3 cm (0.01) 0.2  0.6 cm (0.28) 0.051
Sway-path 9.2  9.5 cm (0.01) 2.8  2 cm (0.16) 9.7  9.5 cm (0.02) 0.13 0.14 0.84 0.01
Max sway 0.3  0.8 cm (>0.05) 0.19  1.1 cm (>0.05) 1.7  2.1 cm (0.01) N/A
UPDRS 0.3  3.4 (0.82) 10.6  5.9 (0.001) 0.02
PLM MT 0.02  0.06 s (0.30) 0.11  0.06 s (0.001) 0.34
Mean difference SEM of the collapsed estimates for themain effects of themixedmodel ANOVA are given with P-values in brackets. Signiﬁcant interactions indicated with P-
values. The different measurements 14 are explained in Fig. 1B.
G. Samoudi et al. / Brain Stimulation 8 (2015) 474e480 477more than 5% between ﬁrst and second assessment, the recording
was re-assessed by a second trained UPDRS examiner and a
consensus score was agreed.
The Posturo-Locomotor-Manual test (PLM) is a repeated move-
ment where the subject picks up an object and transfers it to a
platform at chin height and 2 m ahead. The total movement time
MT(s) is composed of three partly overlapping movement phases:
Postural, where the test person stands up while lifting the object,
Locomotive, when the person walks and Manual, where the person
transfers the object from a holding position to the top of the plat-
form. The movement is recorded using infrared motion capture
technique as previously described [19]. The optoelectronic
measuring system consisted of an infrared camera, reﬂective
markers, and an automated tracking software system (Qbtech/
PDMonitor, Qbtech AB, Sweden). The test movement was carried
out in 10 triplets at each evaluation point and the mean movement
time of the three fastest consecutive movements was used asMT(s).Statistical analysis
Statistical analysis was performed after unblinding. Logarithmic
transformations were made to normalize data distributions. All
data except maximum sway passed normal distribution tests. Non
parametric Friedman test, withWilcoxon’s paired test as a post-hoc
measure was use to analyses maximum sway. Other variables were
analyzed with linear mixed model analyses (ﬁxed-effect, repeated
measures) to assess the main effects of SVS and LDOPA treatment as
well as interaction between the two. In the static posturography,
reduced proprioceptive input was used as a third main factor. All
statistical analysis was performed using SPSS (PASW Statistics 18).
All data are reported as mean  SD, unless otherwise indicated.Results
The sinusoidal current thresholds determined prior to 0 mV
sham stimulation were 0.500  0.245 mA and the SVS maximum
currents (based on another sinusoidal threshold determination) of
the active stimulation sessionswere 0.500 0.255mA (mean SD)
(Table 1). None of the subjects could determine in which session
SVS was active. The examiners were also successfully blinded
throughout the course of the data collection. Four patients reported
six adverse effects during the evaluation. There were four reports of
adverse effects during active stimulation and two in the sham
condition. The adverse effects during active SVS consisted of slight
or more pronounced nausea with vomiting in response to the
LDOPA administration and one patient that reportedmild headache
and dizziness. One patient reported slight vertigo during move-
ment in the sham condition, but not during active stimulation. Thepatient that vomited in response to LDOPA during SVS only re-
ported slight discomfort in the sham condition (Table 1).
In the dynamic balance test, SVS shortened the mean response
time(s) of the perturbation correction (FSVS(1,8.9) ¼ 16.3, P  0.01,
Table 2, Fig. 2A). Post-hoc analysis was not signiﬁcant but the
largest difference between SVS and sham SVS was observed in the
off medication state where the correction time was 0.42  0.14 s
during SVS and 0.46  0.10 s during sham SVS. The new stable AP
position after the balance correction during SVS was slightly pos-
terior to that during sham SVS (FSVS(1,7.54) ¼ 5.48, P  0.05,
Table 2). Furthermore, the maximum backward COP excursion in
relation to the new stable position was decreased by SVS
(FSVS(1,8) ¼ 12.94, P  0.01, Table 2, Fig. 2B), in particular in the off
medication state where the excursion was reduced
from0.057 0.025 to0.0410.019m, with amean reduction of
0.017 m (P < 0.01). There was also a main effect of SVS reducing the
mediolateral deviation during the correcting response
(FSVS(1,8.3) ¼ 14.4, P  0.01, Table 2, Fig. 2C). Although maximum
excursion can be expected to depend on the response time, there
was no correlation between the two variables (Spearman
r ¼ 0.1811, P ¼ 0.30) No signiﬁcant main effect of LDOPA was
observed for perturbed postural responses.
In the static balance test there was a main effect of SVS with
shorter COP sway-path compared to sham (FSVS(1,9.9) ¼ 11.02,
P  0.01, Fig. 2D). As expected, sway-path was signiﬁcantly
increased during reduced proprioceptive input (FFoam(1,10.0) ¼ 9.0,
P¼ 0.02, Table 2, Fig. 2D) and there was also a signiﬁcant three-way
interaction (FSVS*LDOPA*Foam(1,10) ¼ 5.2, P  0.05). Post-hoc analysis
demonstrated a signiﬁcantly reduced sway-path with SVS
(0.73  0.3 m) compared to sham SVS (0.93  0.5 m, P  0.01) off
medication. The Friedman non-parametric test showed that the
max sway deviation was different between the eight different
conditions (c2(7) ¼ 40.13, P < 0.001, Table 2, Fig. 2E). A paired post-
hoc (Wilcoxon’s signed rank) conﬁrmed that maximum sway was
always smaller on a stable surface than on a foam surface (all post-
hoc comparisons foam vs. no foam, Z  2.6, P < 0.01), but sig-
niﬁcant effects of LDOPA or SVS were not found.
There was a signiﬁcant main effect of LDOPA with decreased
UPDRS-III motor scores (FLDOPA(1,9.5) ¼ 76.15, P  0.001, Table 2,
Fig. 2F) and a signiﬁcant interaction effect between SVS and LDOPA
(FSVS*LDOPA (1,9.9) ¼ 7.05, P ¼ 0.02). The interaction effect is mainly
explained by reduced UPDRS-III scores during active SVS
(28.8  10.1) compared to sham SVS (31.2  10.8) off medication
(mean change2.4 2.0), but the post-hoc test was not signiﬁcant.
There was a main effect of LDOPA treatment on PLM movement
times (FLDOPA(1,9.5) ¼ 27.08, P  0.001, Table 2), but no main effect
of SVS. The PLM test is clinically categorized as positive if there is a
signiﬁcant improvement in MT after LDOPA. With SVS 7 of the
patients were positive in the PLM LDOPA test vs. 5 of the patients
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Figure 2. Posturography and UPDRS-III results. Statistics given in Table 2; A) SVS shortened the response time (measure 1 in Fig. 1) from force release until the reactive center of
pressure (COP) movement had changed direction; B) Maximum anterioposterior (AP) center of pressure (COP) deviation (cm) from the post release stable position (measure 3 in
Fig. 1); C) COP deviations in the mediolateral direction during the corrective response after force release were reduced during SVS (measure 4 in Fig. 1); D) total COP sway-path
distance while standing with eyes closed during 10 s of standing still on narrow support; E) the maximum sway deviation during 10 s of standing still with eyes closed; F)
UPDRS scores before and after LDOPA in the SVS and sham stimulation conditions. SVS ¼ stochastic vestibular stimulation, OFF ¼ no medication, ON ¼ after 200 mg LDOPA. Post hoc
test statistics: **P  0.01.
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matched pair, P ¼ 0.25).Discussion
The primary aim of this pilot study was to evaluate the safety
and feasibility of SVS in PD patients. A secondary aimwas to provide
an indication of possible efﬁcacy regarding balance and motor
symptoms in PD. In this small sample, SVS was overall safe to use in
PD patients, but exaggerated nausea after LDOPA challenge was
observed. The LDOPA challenge with 200 mg of LDOPA will in our
experience rarely lead to vomiting, although nausea is not un-
common. If SVS is used outside the experimental setting the po-
tential interaction with LDOPA leading to increased side effects of
the dopaminergic drugs should be considered. SVS improved both
static and dynamic balance indices whereas improvements of
overall motor symptoms were not clearly demonstrated.To maintain the blinding of the study, great care was taken to
minimize any skin sensation of the SVS. Those elaborate procedures
wouldmake SVS unpractical for domestic use, but are not necessary
when slight skin sensations are acceptable. As more pronounced
sensations are norm with transcutaneous electrical nerve stimula-
tion (TENS), we think home use of SVS with regular adhesive
electrodes is feasible.
Previous studies have evaluated the effect of SVS on motor
symptoms using waist and wrist-born accelerometers [7,8] that
provide measures that are difﬁcult to translate to a clinically
meaningful effect. We therefore used the better validated and
widely accepted UPDRS motor rating section. This is the ﬁrst study
evaluating the effect of SVS with UPDRS. Although the effect of SVS
on UPDRS-III was small and not in the range of what is usually
considered as clinically signiﬁcant in individual cases [20] it is
interesting that all improvements (also balance responses) were
found in the off-medication state, as it suggests that SVS may
reduce motor off ﬂuctuations. The effect size of the improved
G. Samoudi et al. / Brain Stimulation 8 (2015) 474e480 479dynamic balance is similar to what we have previously observed
with DBS in PD patients [21], which is promising. Ultimately, novel
treatments for balance problems need to demonstrate reduced
frequency of falls and that would be an important objective of
future studies of SVS in PD. It should be noted that previous studies
have used a somewhat different stimulation protocol. Instead of
white noise, a “pink” 1/f noise proﬁle was used and a nociceptive
threshold was used to decide the maximum amplitude [7,8]. The
stimulation used here is a near-threshold paradigm, where the
threshold for subjective or objective detection of rhythmic syn-
chronized stimulation was used as the maximum allowed current.
This does not mean that the vestibular system is not activated, only
that the activation is not perceived. The SVS amplitudes were
similar to those reported in previous work [7,8] where stimulation
currents where slightly lower (around 0.3 mA) compared to this
study (0.5 mA). In a study of SVS effects on balance function in
healthy individuals [6], maximum improvements occurred with
stimulation amplitudes in a range predominantly between 0.1 and
0.4 mA (mean ¼ 0.26, one subject with the optimal stimulation
level 0.7 mA) using the same 0e30 Hz ﬁltered stochastic protocol
that was used here. Often SR is described in the context of signal
detection. There is some controversy in regard to the linearity of the
afferent side of the vestibular system [22], but regardless of
whether there can be SR at the level of the vestibular system the
corrective postural motor responses are gated by basal ganglia ac-
tivity which is a non-linear selective function where SR can take
place. If SR is involved in the observed effects we ﬁnd it more likely
that it occurs in the selection and activation of motor programs.
There are theoretical models that predict that low dopamine levels
are associated with less neuronal noise and that increasing the
noise in a low dopamine systemwill be associated with larger noise
beneﬁt [23,24], and also that more noise is needed to reach optimal
beneﬁt [24]. Those predictions are in agreement with the obser-
vation that SVS improved functions more before than after LDOPA
administration. A ceiling effect of LDOPA in the current study is also
possible.
It was previously shown that patients with Parkinson’s disease
have a decreased vestibulocollic reﬂex asmeasuredwith vestibular-
evoked myogenic potentials, and that LDOPA restores this deﬁcit
[25]. An expected effect of subthreshold SVS is to increase the
responsivity of a suppressed vestibular system. It is therefore
possible that SVS, similar to LDOPA, ameliorates the reduced ves-
tibulospinal responses in PD. In agreement with that, we found that
SVS reduced the overall COP sway-path, particularly in the off
medication state when standing on foam. Standing on foam makes
the proprioceptive inputs less reliable, so with eyes closed the
subject has to rely more on the vestibular system to maintain bal-
ance. SVS also had a positive effect on perturbed dynamic balance
with reduced excursions in the anterioposterior and mediolateral
plane as well as improvement of the balance response time. We
expected the anterioposterior COP sway distance to be strongly
correlated to the response time, but this was not the case (data not
shown). Independent improvements of response time and COP
excursion suggest that SVS has a positive effect on the reactivity of
the balance system, as well as on the correcting motor response.
The ﬁnding that LDOPA medication had little positive effect on
the static and perturbed balance conditions is consistent with
previous observations [26]. One reason for this could be that
dopaminergic drugs decrease stiffness and can lead to dyskinesia,
which, even when subtle, could affect postural balance negatively
[2]. Overall dopaminergic treatment ameliorates appendicular
symptoms more than axial symptoms. Automatic postural control
may be more improved by facilitating the vestibulospinal control
system or other non-dopaminergic pathways that are activated by
SVS. One of those pathways may involve altered activity in the SNr,as increases in GABA release in the SNr can result from both SVS and
from LDOPA treatment [13]. Interestingly, it was recently reported
that high-frequency DBS of the SNr improves axial symptoms and
gait, when combined with DBS in the STN [27]. We suggest that SVS
and DBS-SNr may in part act through a common mechanism by
inhibiting the overactive SNr [28]. There was a signiﬁcant interac-
tion between SVS and LDOPA in the overall motor score suggestive
of reduced symptoms in OFF. The same pattern was however not
observed in the PLM test, which assesses mainly speed of move-
ment. Although it is interesting that more patients improved
signiﬁcantly in MT after LDOPA during active SVS, this may be a
random result because the study is underpowered for categorical
data. Effect sizes of SVS on overall motor symptoms appear to be
much smaller than those of LDOPA, so to conﬁrm or dismiss a
general motor improvement of SVS in PD, large studies would be
required.
One of the most devastating complications to Parkinson’s dis-
ease is falls [29]. This problem increases and becomes less treat-
ment responsive as the disease progresses. Although the dynamic
balance test used here is a surrogate marker, and responses were
not completely normalized by SVS, PD patients who report falls
could potentially beneﬁt from long term use of SVS. We conclude
that it is feasible to perform blinded or open studies of SVS in PD
and that the effects observed in this pilot study indicate that such
studies should focus on patients with balance and gait problems in
particular.
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